{"entity":{"id":"nct07449754","kind":"trial","name":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","aka":[],"tldr":"A phase 2 trial of Cobimetinib in melanoma, run by Hanmi Pharmaceutical Company Limited, now recruiting.","summary":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma is a phase 2 interventional study registered as NCT07449754 by Hanmi Pharmaceutical Company Limited, with 45 participants planned, started 2026-02-12 and due to reach its primary completion in 2029-09. Interventions recorded: Belvarafenib, Cobimetinib. Conditions listed: Advanced or Metastatic Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07449754","url":"https://clinicaltrials.gov/study/NCT07449754"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cobimetinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07449754","phase":"2","setting":"A Phase 2, Multicenter, Single-Arm Study of Belvarafenib (HM95573) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","sponsor":"Hanmi Pharmaceutical Company Limited","enrolled":45,"outcomes":[]},"route":"/trials/nct07449754/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/"}]}}